乐观
$80.72
情景价格
$154.710
+2.630 (+1.70%)收盘时
Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Latest Wall Street Ratings and Price Target Adjustments

Revvity to Release Q3 2026 Financial Results

Chipmakers' Stocks Rebound Amid Market Volatility

Revvity Acquires HCD to Enhance Life Sciences Tools for Metabolic Drug Discovery

Revvity Reports Strong Q2 2026 Earnings with Raised Guidance
Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。